[Phase III clinical trial on meisoindico in the treatment of chronic myelogenous leukemia].
OBJECTIVE
For further investigating the efficacy and side effects of meisoindico.


METHODS
Four handred and two cases of chronic myelogenous leukemia (CML) were treated with meisoindico alone on the dosage of 75-150mg/day.


RESULTS
The total response rate was 90.1% and the complete and partial remission rates were 81.3%. The effect was better in patients with newly diagnosed CML than in those previously treated. The major side effects were bone, joint and muscle pain of varying degrees. No impairment of cardiac, renal and hepatic function were found. None of the patients developed severe myelosuppression.


CONCLUSIONS
Meisoindico is a novel effective drug for CML.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents